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Background: The conversion of arginine into citrulline, termed citrullination, has important consequences for the
structure and function of proteins. Studies have found PADI4, an enzyme performing citrullination, to be highly
expressed in a variety of malignant tumours and have shown that PADI4 participates in the process of
tumorigenesis. However, as citrullinated proteins have not been systematically investigated in tumours, the present
study aimed to identify novel citrullinated proteins in tumours by 2-D western blotting (2-D WB).
Methods: Two identical two-dimensional electrophoresis (2-DE) gels were prepared using extracts from ECA, H292,
HeLa, HEPG2, Lovo, MCF-7, PANC-1, SGC, and SKOV3 tumour cell lines. The expression profiles on a 2-DE gel were
trans-blotted to PVDF membranes, and the blots were then probed with an anti-citrulline antibody. By comparing
the 2-DE profile with the parallel 2-D WB profile at a global level, protein spots with immuno-signals were collected
from the second 2-DE gel and identified using mass spectrometry. Immunoprecipitation was used to verify the
expression and citrullination of the targeted proteins in tumour cell lines.
Results: 2-D WB and mass spectrometry identified citrullinated α-enolase (ENO1), heat shock protein 60 (HSP60), keratin 8
(KRT8), tubulin beta (TUBB), T cell receptor chain and vimentin in these cell lines. Immunoprecipitation analyses verified
the expression and citrullination of ENO1, HSP60, KRT8, and TUBB in the total protein lysates of the tumour cell lines.
Conclusions: The citrullination of these proteins suggests a new mechanism in the tumorigenic process.
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Citrullination, or deimination, is the post-translational
modification of arginine into citrulline. This conversion
has important consequences for the structure and function
of proteins because arginine is positively charged at a
neutral pH and citrulline is uncharged. Accordingly,
citrullination increases the hydrophobicity of a protein,
leading to alterations in protein folding [1]. Arginine
residues frequently function as ligand recognition sites in
proteins, and some enzymes that interact with negatively
charged substrates or cofactors have an arginine residue
as an anion recognition site [2]. Therefore, it is highly
possible that citrullination participates in regulating
the activities of these enzymes. In addition, it has been
suggested that citrullination modifies the action of trypsin-
like enzymes and trypsin inhibitors, interferes with* Correspondence: changxt@126.com
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reproduction in any medium, provided the orintermediate filament assembly, and plays a role in rapid
cellular turnover in tissues with secretory activity [3-5].
Citrullination is performed by enzymes called peptidy-
larginine deiminases (PADs). Genes encoding PAD fam-
ily members, including PADI1, PADI2, PADI3, PADI4,
and PADI6, cluster at human chromosome position
1p36.13, and the expression of each of these isoforms
has been detected in numerous tissues [6]. Studies have
reported that PADs are involved in cell differentiation,
apoptosis, nerve growth, embryonic development, and
gene regulation [7,8].
Cancer is one of the leading causes of death in
humans. In recent years, studies have found that PADI4 is
markedly over-expressed in a majority of human cancers,
suggesting that PADI4 is a putative target for cancer treat-
ment [9-11]. We recently also reported that the PADI4
gene may be a valid susceptibility gene for oesophageal
carcinoma [12]. Cherrington et al. recently detected
the unique expression of PADI2 in human mammarytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Therefore, the identification of citrullination substrates is
helpful for understanding the pathogenic mechanisms
of PADs during tumorigenesis. Thus far, transcription
factors, coregulators, and histones have been found to
be functional targets for citrullination by PADs, with the
citrullination of these targets affecting gene expression
in multiple tumour cell lines [14]. Yao et al. and Li et al.
found that citrullination and methylation modifications
are antagonistic to each other, indicating a conserved
posttranslational regulatory strategy [15,16]. Li et al. also
demonstrated an important crosstalk between histone
deacetylation and citrullination, suggesting a combination
of PADI4 and histone deacetylase 2 inhibitors as a potential
strategy for cancer treatment [17]. Tanikawa et al. detected
the in vivo and in vitro citrullination of the arginine 3 resi-
due of histone H4 in response to DNA damage through
the p53-PADI4 pathway. These authors also showed
that the ectopic expression of PADI4 leads to chromatin
decondensation and promotes DNA cleavage [18]. Guo
et al. used a high-density protein array as a primary screen
to identify 40 previously unreported PADI4 substrates,
reporting that PADI4 citrullinates the Arg-Gly repeat
region of 40S ribosomal protein S2, which is also an
established site for Arg methylation by protein arginine
methyltransferase 3 [19]. Post-translational modifications
of the extracellular matrix are also key events in cancer
progression: it has been confirmed that the citrullination
of cytokeratin, antithrombin, fibronectin, and ADAMTS4
(a disintegrin and metalloproteinase with thrombospondin
motifs-4) is involved in abnormal apoptosis, high coagu-
lation properties, and disordered cell proliferation and
differentiation, all of which are main features of malignant
tumours [20-25]. Therefore, the precise knowledge of
citrullination modifications of a protein can provide
invaluable information regarding the aetiological import-
ance of these citrullinated proteins.
Although several proteins, such as filaggrin, fibrin, and
vimentin are confirmed substrates of PADs, citrullinated
proteins in tumours have not been systematically investi-
gated to date. In the present study, we aimed to identify
novel citrullinated proteins in tumours using a proteomic
method and 2-D western blotting (2-D WB). Because
tumour tissues contain both tumour cells and normal cells,
and because tissue structures develop with the pro-
gress of pathophysiological conditions, we screened
the citrullinated proteins in various cultured tumour
cell lines. This method is regarded by many as a sound
approach to effectively identify common features of
tumour tissues under variable conditions.
We employed two identical, two-dimensional electro-
phoresis (2-DE) gels per experiment to analyse several
tumour cell lines and then trans-blotted the expression
profiles of one of the 2-DE gels to a polyvinylidenefluoride (PVDF) membrane to perform western blotting
(WB) by probing with an anti-citrulline antibody. By com-
paring the expression profiles of the 2-DE gel to the re-
sults of the parallel WB, the protein spots recognised by an
immuno-signal were collected from the 2-DE gel and iden-
tified using mass spectrometry. The proteins that were
recognised by the anti-citrulline antibody were regarded as
citrullinated proteins in the tumour cell lines. Immunopre-
cipitation was performed to verify the citrullination of the
targeted proteins in the tumour cell lines.
Methods
Cell cultures
ECA (originating from oesophageal carcinoma), HEPG2
(originating from liver cancer), SKOV3 (originating from
ovarian cancer), MCF-7 (originating from breast cancer),
H292 (originating from lung cancer), HeLa (originating
from cervical cancer), Lovo (originating from colon cancer),
OS-RC (originating from kidney cancer), PANC-1 (origin-
ating from pancreatic cancer), and SGC (originating from
gastric cancer) were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% foetal calf serum,
50 U/mL penicillin, and 50 μg/mL streptomycin in an
atmosphere of 5% CO2 at 37°C.
Two-dimensional electrophoresis and two-dimensional
western blot analysis
The samples of the cultured cells were collected and
homogenised in lysis buffer (7 M urea, 2 M thiourea,
4% CHAPS, 2% IPG buffer, 65 mM DTT, and 1 mM
PMSF) with Protease Inhibitor Cocktail (Sigma, USA) on
ice and then centrifuged at 14,000 × g for 30 min.
Isoelectric focusing (IEF) was performed identically twice
using an Ettan IPGphor II IEF system (GE Healthcare,
USA) with Immobiline Drystrips (7 cm, NL, pH 3–10)
(GE Healthcare). After rehydration, 100 μg of protein was
rehydrated with an appropriate quantity of rehydration
buffer [7 M urea, 2 M thiourea, 4% CHAPS, and 0.5%
IPG buffer, pH 3–10 (GE Healthcare), with 0.001%
bromophenol blue]. The IEF voltage was applied according
to the following protocol: 30 V for 12 h, 150 V for 2 h,
3,000 V for 30 min, 5,000 V for 30 min, linear ramping to
8,000 V over 1 h, and then 8,000 V until 10,000 V-h was
reached. Prior to the second dimension separation, the
strips were equilibrated in two successive buffers (6 M
urea, 2% SDS, 50 mM Tris–HCl, pH 8.8, 30% glycerol,
and a trace of bromophenol blue). The first buffer
contained 1% w/v DL-dithiothreitol, and the second
contained 2.5% w/v iodoacetamide. Each equilibration
was conducted for 15 min with continuous agitation.
The strips were then rinsed in electrophoresis buffer
(25 mM Tris base, 192 mM glycine, and 0.1% w/v SDS),
applied to 12.5% acrylamide gels (80 mm × 70 mm),
and sealed with melted agarose (0.5% w/v agarose in
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blue). Electrophoresis was conducted using the Mini PRO-
TEAN Tetra Cell (Biorad, USA) with an initial separation
at 80 V for 10 min, followed by 200 V at 25°C until the
dye front had migrated to the bottom.
After electrophoresis, one gel was visualised by staining
with Coomassie brilliant blue R350 staining solution
overnight. The gel was scanned with a UMAX Powerlook
2100XL (UMAX Technologies, USA), and the digitised
images were analysed with ImageMaster 2D Platinum
software 5.0 (GE Healthcare).
The proteins on another gel were trans-blotted onto a
PVDF membrane using a Mini-PROTEAN® 3 vertical
electrophoresis chamber (Biorad) following the manufac-
turer’s instructions to conduct a 2-D WB analysis. The
membrane was probed with an anti-citrulline antibody
(Abcam, USA) that was raised with conjugated citrulline
glutaraldehyde protein in rabbits. The antibody specificity
was verified with an ELISA. This polyclonal antibody
recognises only citrulline residues on proteins and not
free citrulline. All of the primary and secondary antibodies
were diluted in 5% non-fat dry skim milk in TBST (0.02
M Tris base and 0.137 M NaCl in distilled water, pH 7.6,
containing 0.1% Tween 20). The immuno-reactive signals
were detected with alkaline phosphatase-conjugated sec-
ondary antibodies and visualised using Western Blotting
Luminol Reagent (Amersham, USA). The western blot
images were acquired on a Typhoon Trio (GE Healthcare).
The 2-DE gel stained with Coomassie blue was compared
to the corresponding western blot results. The protein
spots in the same positions as the immuno-signals were ex-
cised manually from the stained gels, washed in MilliQ
water, de-stained in 50 mM ammonium bicarbonate/50%
acetonitrile (ACN) buffer, dehydrated in 100% ACN for 15
min, and then completely dried by vacuum centrifugation.
The dried gel pieces were suspended in trypsinisation buffer
(10 ng/μL trypsin and 25 mM NH4HCO3, pH 8.0) for 30
min at 4°C and incubated overnight in 10 mL 25 mM
NH4HCO3 at 37°C. Lastly, the peptides were extracted with
5% trifluoroacetic acid (TFA)/50% ACN (v/v), and the ex-
tract was lyophilised and re-dissolved in 0.1% TFA/30%
ACN (v/v).
Matrix-assisted laser desorption/ionisation time-of-flight/
time-of-flight mass spectrometry (MALDI-TOF/TOF MS)
analysis and protein identification
A total of 0.5 μL of peptide sample was mixed with an
equal volume of 5 mg/mL α-cyano-4-hydroxycinnamic
acid matrix (Bruke, Sweden) in 0.1% TFA/50% ACN and
spotted onto a standard 192-well plate (ABI). Six external
standards (mass standard kit for the 4700 Proteomics
Analyzer calibration mixture, ABI) were used to calibrate
each spectrum to a mass accuracy within 50 ppm. The
mass spectrometry analysis was performed using an ABI4700 Proteomics Analyzer MALDI-TOF/TOF mass spec-
trometer (ABI) using a batch-mode acquisition method.
The spectral data were analysed with the international pro-
tein index human database v3.10 (57,478 sequences and
25,254,519 residues) using GPS explorer TM software
version 3.0 and Mascot 2.0 software (Matrix Science,
UK). Protein identification was completed using Mascot
software, the benchmark for the identification, character-
isation, and quantitation of proteins using mass spectrom-
etry data. The Mascot search parameters were as follows:
database, Swiss-Prot; fixed modifications, carbamidomethy;
peptide tol, 0.15 kDa; up to 1 missed cleavage allowed.
Immunoprecipitation
The total proteins were purified from the cultured ECA,
PANC-1, SKOV3, HeLa, SGC, and HEPG2 cells using a
Total Protein Extraction kit (Biochain, USA) in accord-
ance with the manufacturer’s instructions. The α-enolase
(ENO1), cytokeratin 8 (KRT8), heat shock protein (HSP60),
protein disulphide isomerase (PDI), T cell receptor beta
chain (TCR β), tubulin B (TUBB), and vimentin (VIME)
proteins in the samples were immunoprecipitated using a
Protein G Immunoprecipitation kit (Sigma) in accordance
with the manufacturer’s instructions. The lysates were in-
cubated with an anti-HSP60 antibody, anti-PDI antibody,
anti-ENO1 antibody, anti-TCR β antibody, anti-VIME
antibody, anti-KRT8 antibody, or anti-TUBB antibody
overnight at 4°C. All antibodies were commercially pro-
duced and obtained from Abcam. Protein G beads provided
with the kit were added to the mixtures and incubated for
2 h at 4°C. After a thorough wash, the extracts were eluted
with 1X Laemmli sample buffer (Sigma). The concentra-
tions of the immunoprecipitates were determined using the
BCA Protein Assay kit (Pierce, USA). A total of 5 μg of pro-
tein sample was separated by SDS-PAGE and trans-blotted
onto PVDF membranes using a western blotting apparatus.
Two membranes were prepared using the same protocol:
one of the membranes was probed with antibodies against
ENO1, KRT8, HSP60, PDI, TCR β, VIME, and TUBB, and
the other was hybridised with the anti-citrulline antibody
(Abcam). Immuno-reactive signals were detected with
alkaline phosphatase-conjugated secondary antibodies
and visualised using Western Blotting Luminol Reagent
(Amersham). The images of the western blots were
acquired using a Typhoon Trio (GE Healthcare).
The Ethics Committee of Shandong Provincial Qianfoshan
Hospital approved this study.
Results
Screen of citrullinated proteins in tumour cell lines by 2-D
western blotting
Following our computational analysis, 200–300 spots were
visualised on each 2-DE gel loaded with total proteins
from various tumour cell lines. In the present study, 263
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from ECA cells, 251 spots from H292 cells, 296 spots from
SGC cells, 270 spots from SKOV3 cells, 284 spots from
HeLa cells, 255 spots from HEPG2 cells, 235 spots
from Lovo cells, 244 spots from MCF-7 cells, and 222
spots from PANC-1 cells. The expression patterns of the
2-DE gels were compared with the expression profiles of
the parallel 2-D WBs at a global level. One protein spot
recognised by the anti-citrulline antibody was detected in
the total protein of the ECA cells in addition to 2 spots
from H292 cells, 1 spot from HeLa cells, 3 spots from
HEPG2 cells, 1 spot from Lovo cells, 2 spots from MCF-7
cells, 2 spots from PANC-1 cells, 3 spots from SGC cells,
and 1 spot from SKOV3 cells. The 2-DE gels and their
corresponding western blots are shown in Figure 1. The
experiments were repeated three times, and the results of
the 2-DE gel and 2-D WB were highly reproducible. The
proteins immuno-stained with the anti-citrulline antibody
were collected from the gels and analysed by MALDI-
TOF/TOF MS. The identified proteins with scores over
70 are shown in Table 1 and were selected for further
study. The mass spectrometry analysis yielded the follow-
ing: ENO1 was detected in the HEPG2, PANC-1, and
SGC cells; HSP60 was detected in the ECA, HeLa, and
SKOV3 cells; TCR β was detected in the HEPG2,
PANC-1, and SGC cells; VIME was detected in the
HEPG2 and PANC-1 cells; PDI was detected in the
H292 cells; TUBB was detected in the SGC cells; and
KRT8 was detected in the MCF-7 cells. No evidentFigure 1 Two-dimensional polyacrylamide gel electrophoresis and th
tumour cell lines. The total proteins extracted from ECA, H292, HeLa, HEP
two identical 2-DE gels. The tumour cell proteins on one gel were trans-blo
antibody. The protein spots in the same position as those recognised by thimmuno-staining was observed on the OR-SC, PC3, or
U2-OS cell WBs.
Verification of citrullination of the candidate proteins in
the cell lines by immunoprecipitation
To verify the above 2-D WB results, immunoprecipitation
experiments were performed using antibodies against
ENO1, HSP60, KRT8, PDI, TCR β, TUBB, and VIME in
the ECA, PANC-1, SKOV3, HeLa, SGC, and HEPG2 cells.
ENO1 (53 kDa), HSP60 (60 kDa), and TUBB (55 kDa)
were immunoprecipitated from the total protein extracts
of ECA, PANC-1, SKOV3, HeLa, SGC, and HEPG2 cells
and detected using western blotting with the anti-citrulline
antibody. KRT8 (53 kDa) was immunoprecipitated from
the total protein extracts of ECA, PANC-1, SKOV3, HeLa,
SGC, and HEPG2 cells and was only detected in the
PANC-1 cell lysate by western blotting using the anti-
citrulline antibody. PDI (58 kDa) was immunoprecipitated
from the total protein extracts of ECA, PANC-1, SKOV3,
HeLa, SGC, and HEPG2 cells, but the protein was not
detected in these tumour cell lines by western blotting
using the anti-citrulline antibody. VIME (57 kDa) was
immunoprecipitated from the total protein extracts of
ECA and PANC-1 cells; although the extracted protein
was recognised in these two tumour cell lines, there
were multiple immuno-signals using the anti-citrulline
antibody. TCR β was not extracted from the total protein
extracts of ECA, PANC-1, SKOV3, HeLa, SGC, and
HEPG2 cells and was not detected by western blottinge parallel 2-D western blotting of total proteins from various
G2, Lovo, MCF-7, PANC-1, SGC, and SKOV3 cells were separated using
tted onto a PVDF membrane and probed with an anti-citrulline
e parallel 2-D WB were selected and identified by MALDI-TOF MS.
Table 1 Identified citrullinated proteins in cultured tumour cell lines using 2-D western blotting
Spots in cell lines MALDI-TOF/TOF MS analysis Identified proteins
ECA 3a Mass: 61187 Score: 133 Expect: 1.2e-08 Matches: 17 60 kDa heat shock protein (HSP60)
H292 6a Mass: 54454 Score: 104 Expect: 9.2e-06 Matches: 11 Protein disulfide isomerase (PDI)
HeLa 1a Mass: 60813 Score: 76 Expect: 0.054 Matches: 6 60 kDa heat shock protein (HSP60)
HEPG2 2a Mass: 50240 Score: 155 Expect: 7.3e-11 Matches: 22 Alpha-enolase (ENO1)
HEPG2 3a Mass: 36628 Score: 102 Expect: 1.5e-05 Matches: 12 T cell receptor beta chain (TCRb)
HEPG2 6a Mass: 53738 Score: 149 Expect: 2.9e-10 Matches: 18 Vimentin (VIME)
Lovo 1a Mass: 48083 Score: 105 Expect: 7.3e-06 Matches: 9 Mitochondrial ATP synthase,
H + transporting F1 complex beta subunit
MCF-7 3a Mass: 53774 Score: 130 Expect: 2.3e-08 Matches: 12 Cytokeratin 8 (KRT8)
PANC-1 1a Mass: 53738 Score: 140 Expect: 2.3e-09 Matches: 17 Vimentin (VIME)
PANC-1 4a Mass: 47481 Score: 120 Expect: 2.3e-07 Matches: 13 Alpha-enolase (ENO1)
PANC-1 4a Mass: 36628 Score: 79 Expect: 0.027 Matches: 9 T cell receptor beta chain (TCRb)
SGC 1a Mass: 50177 Score: 70 Expect: 0.026 Matches: 10 Tubulin beta (TUBB)
SGC 2a Mass: 36628 Score: 113 Expect: 1.2e-06 Matches: 11 T cell receptor beta chain (TCRb)
SGC 3a Mass: 47481 Score: 172 Expect: 1.5e-12 Matches: 15 Alpha-enolase (ENO1)
SKOV 3a Mass: 61187 Score: 103 Expect: 1.2e-05 Matches: 14 60 kDa heat shock protein (HSP60)
Jiang et al. World Journal of Surgical Oncology 2013, 11:260 Page 5 of 8
http://www.wjso.com/content/11/1/260using the anti-citrulline antibody. The immunoprecipitation
results are shown in Figure 2 and were highly reproducible
in three repeat experiments.
Discussion
In the present study, we conducted a 2-D WB analysis with
cultured tumour cell lines. Western blotting was performed
with an anti-citrulline antibody, and the protein spots in
the same locations as the immuno-signals detected by WB
were identified using mass spectrometry. ENO1, HSP60,
KRT8, PDI, TCRβ, TUΒΒ, and VIME were identified in the
tumour cell lines using 2-D WB, and immunoprecipitation
verified that ENO1, HSP60, KRT8, and TUBB were
expressed and citrullinated in these cell lines, as described
above. These results indicate that ENO1, HSP60, KRT8,
and TUBB are novel proteins with citrullination in tumour
tissues.
From the results, it can be observed that the amount
of citrullinated proteins identified by 2-D WB was much
reduced in comparison to those that were immunopre-
cipitated. Immunoprecipitation is a technique for pulling
a protein antigen out of solution using an antibody that
specifically binds to that particular protein. Therefore,
citrullinated proteins are accumulated by immunopre-
cipitation, and the quantity of citrullinated protein in
the experiment is much more than that observed by 2-D
WB. The citrullinated proteins identified by 2-D WB
differed greatly in the different cell lines used in this
study, as these lines originate from different tissues.
Although citrullination is common in tissues, the physio-
logical role and pathogenic mechanism of the citrullinatedprotein may be different in different tissues or at different
pathological stages. In addition, this study used Immobiline
Drystrips 7 cm in length, and a 100-μg protein sample
was loaded onto the gel; thus, it is reasonable to obtain
200–300 spots in a 7-cm gel length.
Functional analyses have shown that ENO1 is an
enzyme, HSP60 is involved in cell signalling pathways,
and KRT8 and TUBB are important components of the
cytoskeleton. These citrullinated proteins could play
similar roles in tumorigenic pathways in different cell
lines, though the detailed mechanism needs further
investigation. ENO1, a homodimeric, soluble protein,
functions in anaerobic metabolism under hypoxic con-
ditions and acts as a cell surface plasminogen receptor
during tissue invasion. The irregular expression of ENO1
has been linked to tumour progression in several cases
of breast and lung cancer, and the ENO1 protein level
in the plasma of non-small cell lung cancer patients was
significantly higher than that in the plasma of healthy
individuals [26]. Furthermore, autoantibodies against ENO1
may serve as a promising biomarker for non-small-cell
lung carcinoma [27]. ENO1 is also over-expressed in head
and neck cancer [28]. It has been reported that ENO1 is
involved in hypoxic. Hypoxia is a central player in cancer
progression, affecting not only tumour cell autonomous
functions, such as cell division and invasion, the resistance
to therapy, and genetic instability, but also non-autonomous
processes, such as angiogenesis and inflammation, all of
which contribute to metastasis [29]. In the present study,
ENO1 was found to be citrullinated in many of these cell





































































































Figure 2 Immunoprecipitation of ENO1, HSP60, KRT8, PDI, TUBB, and VIME in ECA, HEPG2, SKOV3, HeLa, PANC-1, and SGC cell lines.
The immunoprecipitation was performed with anti-ENO1, -HSP60, -KRT8, -PDI, -TUBB, or -VIME antibodies to extract the corresponding proteins.
Western blotting was performed with anti-ENO1, -HSP60, -KRT8, -PDI, -TUBB, -VIME, and anti-citrulline antibodies to determine the citrullination of
these candidate proteins. The thick arrow indicates the candidate proteins. The thin arrow indicates the molecular weights of the protein marker.
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oxidative stress of tumours, thereby contributing to can-
cer progression.
HSP60 is a mitochondrial chaperonin that is typically
responsible for the transportation and refolding of proteins
from the cytoplasm into the mitochondrial matrix. In
addition to its role as a heat shock protein, HSP60
functions as a chaperonin, assisting in the folding of
linear amino acid chains into their respective three-
dimensional structures. HSP60 has been shown to influ-
ence apoptosis in tumour cells, and this influence appears
to be associated with a change in its expression level [30].
HSP60 inhibitors may function as potential anticancer
agents by differentially inducing apoptosis in tumour
cells [31]. The HSP60 protein is over-expressed in poorly
differentiated prostate cancers [32], and HSP60 mRNA
levels were significantly higher in primary breast cancer
tissues compared to healthy breast tissues. Moreover,
HSP60 over-expression during the first steps of breast
carcinogenesis may be functionally correlated to tumour
growth and/or progression [33]. In addition, cytosolic
HSP60 is likely to be a regulatory component of the
IkappaB kinase complex, thus implicating the firstmitochondrial factor to regulate cell survival via the
NF-kappaB pathway [34]. In the present study, we
detected HSP60 expression in the oesophageal carcinoma
cell line, cervical cancer cell line, and ovarian cancer cell
line. Immunoprecipitation also indicated citrullination
of the protein in various tumour cell lines. These results
are in accordance with previous reports and suggest the
involvement of citrullinated HSP60 in the tumorigenic
process.
Unregulated migratory and invasive characteristics are
common features of all cancers [35]. Microtubules are
intracellular structures formed by the protein tubulin that
have a number of essential cellular functions, including
chromosome segregation, the maintenance of cell shape,
transport, and motility, and organelle distribution. A
previous genetic analysis indicated a strong association
of the TUBB gene with non-small-cell lung cancer [36]. In
cases of ovarian carcinoma, high expression levels of class
III beta-tubulin appeared to be associated with earlier re-
currence [37]. Drugs that affect the tubulin-microtubule
equilibrium (Taxol and Vinca alkaloids) are effective anti-
cancer drugs [38]. Cytokeratins are intermediate filament
keratins found in the intracytoplasmic cytoskeleton of
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filament proteins expressed in single-layered epithelia
of the gastrointestinal tract, and KRT8/18 expression
differentiates distinct subtypes of grade 3 invasive ductal
carcinoma of the breast [39]. Keratin 8/18 is broken down
and reorganised during apoptosis [40]. The present study
detected the expression and citrullination of TUBB in
ECA, PANC-1, SKOV3, HeLa, SGC, and HEPG2 cells,
as well as the expression and citrullination of KRT8 in
ECA, PANC-1, SKOV3, HeLa, SGC, and HEPG2 cells.
The above results in conjunction with previous studies
suggest that the citrullination of TUBB and KRT8 may
contribute to tumour growth and invasion and a poor
prognosis.
Conclusions
The current study identified novel citrullinated proteins,
including ENO1, HSP60, KRT8, and TUBB, in tumour
cells. Citrullination is a type of post-translation modifi-
cation that leads to the alternation of enzyme activity
and cell behaviour. Thus, the identification of novel
citrullinated proteins in tumour cell lines is helpful to
further the understanding of the tumorigenic process.
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